IRVINE, Calif.--(BUSINESS WIRE)--Aug. 25, 2023--
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September:
Event: Wells Fargo Healthcare Conference
Date: Friday, September 8
Presentation time: 10:15 a.m. Eastern Time
Event: Morgan Stanley Healthcare Conference
Date: Monday, September 11
Presentation time: 10:00 a.m. Eastern Time
Event: Baird Healthcare Conference
Date: Tuesday, September 12
Presentation time: 3:10 p.m. Eastern Time
Event: CL King Best Ideas Conference
Date: Monday, September 18
Presentation time: 12:30 p.m. Eastern Time
Interested parties may access a live webcast and replay of each presentation by visiting the Axonics investor relations website.
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500.
Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230825786972/en/
Source: Axonics, Inc.